Swiss drugmaker Roche has said it is on track to control just over 96 percent of Genentech.
That ends a long drawn-out battle by Roche to get the 44 percent of the US biotech group’s shares that it did not already own. It will have cost Roche the equivalent of 34.4 billion euros. It wanted Genentech for its lucrative anti-cancer drugs. This was the latest in a series of major mergers in the pharmaceutical sector this year.